Nexgel Inc (NXGL) FinancialsNXGLNexgel Inc

Nexgel Inc (NXGL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Nexgel, accounting for 73.4% of total sales, equivalent to $1.95M. Another important revenue stream is CGN JV. Understanding this composition is critical for investors evaluating how NXGL navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Nexgel Inc maintains a gross margin of 30.09%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -67.96%, while the net margin is -97.83%. These profitability ratios, combined with a Return on Equity (ROE) of -128.61%, provide a clear picture of how effectively NXGL converts its operational activities into shareholder value.

In the context of the broader market, NXGL competes directly with industry leaders such as TANH and SDST. With a market capitalization of $3.70M, it holds a significant position in the sector. When comparing efficiency, NXGL's gross margin of 30.09% stands against TANH's 20.61% and SDST's N/A. Such benchmarking helps identify whether Nexgel Inc is trading at a premium or discount relative to its financial performance.

Nexgel's total revenue for Q2 2026 was $3.686 million, but it reported a net income loss of $3.635 million, highlighting ongoing profitability issues. The gross margin for Q2 2026 was 30.09%, which is lower than previous quarters, indicating declining efficiency.